Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Immunology
ianalumab - BAFF-R inhibitor
2023 priorities
Innovation: Clinical trials
Neuroscience
Oncology
ianalumab - BAFF-R inhibitor
Appendix
Abbreviations
Other
NCT03217422 AMBER (CVAY736B2201)
Indication
Autoimmune hepatitis
Phase
Phase 2
Patients
65
Primary
Outcome
Alanine aminotransferase (ALT) normalization
Measures
Arms
VAY736
Intervention
Target
Placebo control with conversion to active VAY736
Autoimmune hepatitis patients with incomplete response or intolerant to
standard treatment of care
Patients
Readout
2024
Milestone(s)
Publication
TBD
NCT05126277 SIRIUS-LN (CVAY736K12301)
Lupus Nephritis
Phase 3
Indication
Phase
Patients
420
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
Frequency and percentage of participants achieving complete renal response
(CRR) [ Time Frame: week 72]
Arm 1: Experimental -ianalumab s.c. q4w in addition to standard of care (SoC)
Arm 2: Experimental - ianalumab s.c. q12w in addition to SoC
Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC
Patients with active Lupus Nephritis
Primary 2027
Publication
TBD
70 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation